(Q37974709)

English

New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors

scientific article published on 11 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors (English)

1 reference

Europe PubMed Central

26 August 2017

1 reference

based on heuristic

inferred from title

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Fabio Blandini

1

1 reference

Europe PubMed Central

26 August 2017

Marie-Therese Armentero

2

1 reference

Europe PubMed Central

26 August 2017

language of work or name

0 references

publication date

11 January 2012

1 reference

Europe PubMed Central

26 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

26 August 2017

21

1 reference

Europe PubMed Central

26 August 2017

2

1 reference

Europe PubMed Central

26 August 2017

153-168

1 reference

Europe PubMed Central

26 August 2017

Unraveling the pathogenesis of Parkinson's disease--the contribution of monogenic forms

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Functional changes of the basal ganglia circuitry in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Non-motor symptoms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Milestones in PD genetics

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Levodopa motor complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Therapies for dopaminergic-induced dyskinesias in Parkinson disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

NMDA receptor subunits: function and pharmacology.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Molecular determinants of AMPA receptor subunit assembly

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Kainate receptors and synaptic transmission

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Metabotropic glutamate receptors: synaptic transmission, modulation, and plasticity.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Metabotropic glutamate receptors in the basal ganglia motor circuit

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Effect of gamma-butyrobetaine on fatty liver in juvenile visceral steatosis mice

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Adenosine A2A receptors and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), dopamine D(2), cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Industry forum: Progress in pursuit of therapeutic A2A antagonists: The adenosine A2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.651457

21 January 2018

Identifiers

10.1517/13543784.2012.651457

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37974709&oldid=2148070784"